Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule

References

• Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012; 22:3-13; PMID:22245472; http://dx.doi.org/10.1016/j.semcancer.2011.12.009
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2015. Mabs 2015; 7:1-8; PMID:25484055; http://dx.doi.org/10.4161/19420862.2015.988944
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2016. Mabs 2016; 8:197-204; PMID:26651519; http://dx.doi.org/10.1080/19420862.2015.1125583
   PubMed Web of Science ®Google Scholar
• Diamandis M, White NMA, Yousef GM. Personalized Medicine: Marking a New Epoch in Cancer Patient Management. Mol Cancer Res 2010; 8:1175-87; PMID:20693306; http://dx.doi.org/10.1158/1541-7786.MCR-10-0264
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Crown J. Companion biomarkers: paving the pathway to personalized treatment for Cancer. Clin Chem 2013; 59:1447-56; PMID:23656699; http://dx.doi.org/10.1373/clinchem.2012.200477
   PubMed Web of Science ®Google Scholar
• Kalia M. Personalized oncology: Recent advances and future challenges. Metab-Clin Exp 2013; 62:S11-S4; PMID:22999010; http://dx.doi.org/10.1016/j.metabol.2012.08.016
   PubMed Web of Science ®Google Scholar
• Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metab-Clin Exp 2015; 64:S16-S21; PMID:25468140; http://dx.doi.org/10.1016/j.metabol.2014.10.027
   PubMed Web of Science ®Google Scholar
• Bussolati G, Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 2008; 61:1184-92; PMID:18326011; http://dx.doi.org/10.1136/jcp.2007.047720
   PubMed Web of Science ®Google Scholar
• Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL. Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev 2010; 19:982-91; PMID:20332259; http://dx.doi.org/10.1158/1055-9965.EPI-10-0097
   PubMed Web of Science ®Google Scholar
• Paavilainen L, Edvinsson A, Asplund A, Hober S, Kampf C, Ponten F, Wester K. The Impact of Tissue Fixatives on Morphology and Antibody-based Protein Profiling in Tissues and Cells. J Histochem Cytochem 2010; 58:237-46; PMID:19901271; http://dx.doi.org/10.1369/jhc.2009.954321
   PubMed Web of Science ®Google Scholar
• Engel KB, Moore HM. Effects of Preanalytical Variables on the Detection of Proteins by Immunohistochemistry in Formalin-Fixed, Paraffin-Embedded Tissue. Arch Pathol Lab Med 2011; 135:537-43; PMID:21526952; http://dx.doi.org/10.1043/2010-0702-RAIR.1
   PubMed Web of Science ®Google Scholar
• Fairley JA, Gilmour K, Walsh K. Making the Most of Pathological Specimens: Molecular Diagnosis in Formalin-Fixed, Paraffin Embedded Tissue. Current Drug Targets 2012; 13:1475-87; PMID:22974391; http://dx.doi.org/10.2174/138945012803530125
   PubMed Web of Science ®Google Scholar
• Howat WJ, Wilson BA. Tissue fixation and the effect of molecular fixatives on downstream staining procedures. Methods 2014; 70:12-9; PMID:24561827; http://dx.doi.org/10.1016/j.ymeth.2014.01.022
   PubMed Web of Science ®Google Scholar
• D'Amico F, Skarmoutsou E, Stivala F. State of the art in antigen retrieval for immunohistochemistry. J Immunol Methods 2009; 341:1-18; PMID:19063895; http://dx.doi.org/10.1016/j.jim.2008.11.007
   PubMed Web of Science ®Google Scholar
• Shi S-R, Shi Y, Taylor CR. Antigen Retrieval Immunohistochemistry: Review and Future Prospects in Research and Diagnosis over Two Decades. J Histochem Cytochem 2011; 59:13-32; PMID:21339172; http://dx.doi.org/10.1369/jhc.2010.957191
   PubMed Web of Science ®Google Scholar
• Burns JA, Li Y, Cheney CA, Ou Y, Franlin-Pfeifer LL, Kuklin N, Zhang ZQ. Choice of Fixative Is Crucial to Successful Immunohistochemical Detection of Phosphoproteins in Paraffin-embedded Tumor Tissues. J Histochem Cytochem 2009; 57:257-64; PMID:19001637; http://dx.doi.org/10.1369/jhc.2008.952911
   PubMed Web of Science ®Google Scholar
• Gruchy JR, Barnes PJ, Hache KAD. CytoLyt (R) Fixation and Decalcification Pretreatments Alter Antigenicity in Normal Tissues Compared With Standard Formalin Fixation. Appl Immunohistochem Mol Morphol 2015; 23:297-302; PMID:25265430; http://dx.doi.org/10.1097/PAI.0000000000000082
   PubMedGoogle Scholar
• Chu WS, Furusato B, Wong K, Sesterhenn IA, Mostofi FK, Wei MQ, Zhu Z, Abbondanzo SL, Liang Q. Ultrasound-accelerated formalin fixation of tissue improves morphology, antigen and mRNA preservation. Modern Pathol 2005; 18:850-63; PMID:15605077; http://dx.doi.org/10.1038/modpathol.3800354
   PubMed Web of Science ®Google Scholar
• Nietner T, Jarutat T, Mertens A. Systematic comparison of tissue fixation with alternative fixatives to conventional tissue fixation with buffered formalin in a xenograft-based model. Virchows Arch 2012; 461:259-69; PMID:22814649; http://dx.doi.org/10.1007/s00428-012-1248-5
   PubMed Web of Science ®Google Scholar
• Bordeaux J, Welsh AW, Agarwal S, Killiam E, Baquero MT, Hanna JA, Anagnostou V, Rimm D. Antibody validation. Biotechniques 2010; 48:197-209; PMID:20359301; http://dx.doi.org/10.2144/000113382
   PubMed Web of Science ®Google Scholar
• Pauly D, Hanack K. How to avoid pitfalls in antibody use. F1000Research 2015; 4:691; PMID:26834988; http://dx.doi.org/10.12688/f1000research.6894.1
   PubMedGoogle Scholar
• Ward JM, Rehg JE. Rodent Immunohistochemistry: Pitfalls and Troubleshooting. Vet Pathol 2014; 51:88-101; PMID:24078006; http://dx.doi.org/10.1177/0300985813503571
   PubMed Web of Science ®Google Scholar
• Hashizume K, Hatanaka Y, Kamihara Y, Kato T, Hata S, Akashi S, Kato T, Koyatsu J, Tani Y, Tsujimoto M, et al. Interlaboratory comparison in HercepTest assessment of HER2 protein status in invasive breast carcinoma fixed with various formalin-based fixatives. Appl Immunohistochem Mol Morphol 2003; 11:339-44; PMID:14663361; http://dx.doi.org/10.1097/00129039-200312000-00011
   PubMedGoogle Scholar
• Ballou B, Ernst LA, Waggoner AS. Fluorescence imaging of tumors in vivo. Curr Med Chem 2005; 12:795-805; PMID:15853712; http://dx.doi.org/10.2174/0929867053507324
   PubMed Web of Science ®Google Scholar
• Levenson RM, Mansfield JR. Multispectral imaging in biology and medicine: Slices of life. Cytometry Part A 2006; 69A:748-58; PMID:16969820; http://dx.doi.org/10.1002/cyto.a.20319
   Web of Science ®Google Scholar
• Zhou L, El-Deiry WS. Multispectral Fluorescence Imaging. J Nucl Med 2009; 50:1563-6; PMID:19759119; http://dx.doi.org/10.2967/jnumed.109.063925
   PubMed Web of Science ®Google Scholar
• Mansfield JR. Multispectral imaging: a review of its technical aspects and applications in anatomic pathology. Vet Pathol 2014; 51:185-210; PMID:24129898; http://dx.doi.org/10.1177/0300985813506918
   PubMed Web of Science ®Google Scholar
• Leblond F, Davis SC, Valdes PA, Pogue BW. Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol B-Biol 2010; 98:77-94; PMID:20031443; http://dx.doi.org/10.1016/j.jphotobiol.2009.11.007
   PubMed Web of Science ®Google Scholar
• Koenig A, Herve L, Josserand V, Berger M, Boutet J, Da Silva A, Dinten JM, Peltié P, Coll JL, Rizo P. In vivo mice lung tumor follow-up with fluorescence diffuse optical tomography. J Biomed Opt 2008; 13; PMID:18315357; http://dx.doi.org/10.1117/1.2884505
   PubMed Web of Science ®Google Scholar
• Yang M, Baranov E, Jiang P, Sun FX, Li XM, Li LN, Hasegawa S, Bouvet M, Al-Tuwaijri M, Chishima T, et al. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci U S A 2000; 97:1206-11; PMID:10655509; http://dx.doi.org/10.1073/pnas.97.3.1206
   PubMed Web of Science ®Google Scholar
• Ntziachristos V, Tung C-H, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 2002; 8:757-60; PMID:12091907; http://dx.doi.org/10.1038/nm729
   PubMed Web of Science ®Google Scholar
• Weissleder R, Tung CH, Mahmood U, Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999; 17:375-8; PMID:10207887; http://dx.doi.org/10.1038/7933
   PubMed Web of Science ®Google Scholar
• Mahmood U, Tung CH, Bogdanov A, Weissleder R. Near-infrared optical imaging of protease activity for tumor detection. Radiology 1999; 213:866-70; PMID:10580968; http://dx.doi.org/10.1148/radiology.213.3.r99dc14866
   PubMed Web of Science ®Google Scholar
• von Wallbrunn A, Hoeltke C, Zuehlsdorf M, Heindel W, Schaefers M, Bremer C. In vivo imaging of integrin alpha nu beta(3) expression using fluorescence-mediated tomography. Eur J Nucl Med Mol Imaging 2007; 34:745-54; PMID:17131149; http://dx.doi.org/10.1007/s00259-006-0269-1
   PubMed Web of Science ®Google Scholar
• Ke S, Wen XX, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 2003; 63:7870-5; PMID:14633715; http://dx.doi.org/10.1371/journal.pone.0046255
   PubMed Web of Science ®Google Scholar
• Becker A, Hessenius C, Licha K, Ebert B, Sukowski U, Semmler W, Wiedenmann B, Grötzinger C. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 2001; 19:327-31; PMID:11283589; http://dx.doi.org/10.1038/86707
   PubMed Web of Science ®Google Scholar
• Bullok KE, Maxwell D, Kesarwala AH, Gammon S, Prior JL, Snow M, Stanley S, Piwnica-Worms D. Biochemical and in vivo characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. Biochemistry 2007; 46:4055-65; PMID:17348687; http://dx.doi.org/10.1021/bi061959n
   PubMed Web of Science ®Google Scholar
• Ntziachristos V, Schellenberger EA, Ripoll J, Yessayan D, Graves E, Bogdanov A, Josephson L, Weissleder R. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A 2004; 101:12294-9; PMID:15304657; http://dx.doi.org/10.1073/pnas.0401137101
   PubMed Web of Science ®Google Scholar
• Oliveira S, Cohen R, Stigter-van Walsum M, van Dongen GAMS, Elias SG, van Diest PJ, Mali W, van Bergen En Henegouwen PM. A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies. Ejnmmi Res 2012; 2(1):50,1-9; PMID:23009555; http://dx.doi.org/10.1186/2191-219X-2-50
   PubMed Web of Science ®Google Scholar
• Suzuki T, Miyazaki C, Ishii-Watabe A, Tada M, Sakai-Kato K, Kawanishi T, Kawasaki N. A fluorescent imaging method for analyzing the biodistribution of therapeutic monoclonal antibodies that can distinguish intact antibodies from their breakdown products. Mabs 2015; 7:759-69; PMID:25891896; http://dx.doi.org/10.1080/19420862.2015.1038683
   PubMed Web of Science ®Google Scholar
• Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69:9330-6; PMID:19934333; http://dx.doi.org/10.1158/0008-5472.CAN-08-4597
   PubMed Web of Science ®Google Scholar
• Peterson NC, Wilson GG, Huang Q, Dimasi N, Sachsenmeier KF. Biodistribution analyses of a near-infrared, fluorescently labeled, bispecific monoclonal antibody using optical imaging. Comparative Med 2016; 66:90-9; PMID:27053562
   PubMed Web of Science ®Google Scholar
• Fuentes G, Scaltriti M, Baselga J, Verma CS. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res 2011; 13(3):R54,1-9; PMID:21600050; http://dx.doi.org/10.1186/bcr2888
   PubMed Web of Science ®Google Scholar
• Maly JJ, Macrae ER. Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival. Breast cancer 2014; 8:81-8; PMID:24855372; http://dx.doi.org/10.4137/BCBCR.S9032
   PubMedGoogle Scholar
• Kawajiri H, Takashima T, Kashiwagi S, Noda S, Onoda N, Hirakawa K. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Exp Rev Anticancer Ther 2015; 15:17-26; PMID:25494663; http://dx.doi.org/10.1586/14737140.2015.992418
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372:724-34; PMID:25693012; http://dx.doi.org/10.1056/NEJMoa1413513
   PubMed Web of Science ®Google Scholar
• Ezaki T. Antigen retrieval: Its significance and drawbacks in immunohistochemistry. Acta Anatomica Nipponica 1996; 71:615-28; PMID:9038004
   PubMedGoogle Scholar
• van den Broek LJCM, van de Vijver MJ. Assessment of problems in diagnostic and research immunohistochemistry associated with epitope instability in stored paraffin sections. Appl Immunohistochem Mol Morphol 2000; 8:316-21; PMID:11127924; http://dx.doi.org/10.1097/00129039-200012000-00009
   PubMedGoogle Scholar
• Riechers A, Bosserhoff AK. Pitfalls in immunohistochemistry - a recent example. Int J Clin Exp Patho 2012; 5:137-9; PMID:22400073
   PubMed Web of Science ®Google Scholar
• Zatovicova M, Sedlakova O, Svastova E, Ohradanova A, Ciampor F, Arribas J, Pastorek J, Pastorekova S. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer 2005; 93:1267-76; PMID:16278664; http://dx.doi.org/10.1038/sj.bjc.6602861
   PubMed Web of Science ®Google Scholar
• Schirrmeister W, Gnad T, Wex T, Higashiyama S, Wolke C, Naumann M, Lendeckel U. Ectodomain shedding of E-cadherin and c-Met is induced by Helicobacter pylori infection. Exp Cell Res 2009; 315:3500-8; PMID:19665015; http://dx.doi.org/10.1016/j.yexcr.2009.07.029
   PubMed Web of Science ®Google Scholar
• Liu PCC, Liu X, Li Y, Covington M, Wynn R, Huber R, Hillman M, Yang G, Ellis D, Marando C, et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 2006; 5:657-64; PMID:16627989; http://dx.doi.org/10.4161/cbt.5.6.2708
   PubMed Web of Science ®Google Scholar
• Higashiyama S, Nanba D, Nakayama H, Inoue H, Fukuda S. Ectodomain shedding and remnant peptide signalling of EGFRs and their ligands. J Biochem 2011; 150:15-22; PMID:21610047; http://dx.doi.org/10.1093/jb/mvr068
   PubMed Web of Science ®Google Scholar
• Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005; 11:5300-9; PMID:16033849; http://dx.doi.org/10.1158/1078-0432.CCR-04-2642
   PubMed Web of Science ®Google Scholar
• Tse C, Gauchez A-S, Jacot W, Lamy P-J. HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer. Cancer Treatment Rev 2012; 38:133-42; PMID:21549508; http://dx.doi.org/10.1016/j.ctrv.2011.03.008
   PubMed Web of Science ®Google Scholar
• Tas F, Bilgin E, Karabulut S, Duranyildiz D. Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer. Cytokine 2015; 71:66-70; PMID:25259789; http://dx.doi.org/10.1016/j.cyto.2014.09.001
   PubMed Web of Science ®Google Scholar
• Wang Z, Lu P, Liang Z, Zhang Z, Shi W, Cai X, Chen C. Increased insulin-like growth factor 1 receptor (IGF1R) expression in small cell lung cancer and the effect of inhibition of IGF1R expression by RNAi on growth of human small cell lung cancer NCI-H446 cell. Growth Factors 2015; 33:337-46; PMID:26430715; http://dx.doi.org/10.3109/08977194.2015.1088533
   PubMed Web of Science ®Google Scholar
• Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol 2014; 24:26-34; PMID:24295852; http://dx.doi.org/10.1016/j.tcb.2013.11.002
   PubMed Web of Science ®Google Scholar
• Reiss K, Saftig P. The “A Disintegrin And Metalloprotease” (ADAM) family of sheddases: Physiological and cellular functions. Semin Cell Dev Biol 2009; 20:126-37; PMID:19049889; http://dx.doi.org/10.1016/j.semcdb.2008.11.002
   PubMed Web of Science ®Google Scholar
• van Kilsdonk JWJ, van Kempen LCLT, van Muijen GNP, Ruiter DJ, Swart GWM. Soluble adhesion molecules in human cancers: Sources and fates. Eur J Cell Biol 2010; 89:415-27; PMID:20227133; http://dx.doi.org/10.1016/j.ejcb.2009.11.026
   PubMed Web of Science ®Google Scholar
• Brezski RJ, Vafa O, Petrone D, Tam SH, Powers G, Ryan MH, Luongo JL, Oberholtzer A, Knight DM, Jordan RE. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci U S A 2009; 106:17864-9; PMID:19815504; http://dx.doi.org/10.1073/pnas.0904174106
   PubMed Web of Science ®Google Scholar
• Brezski RJ, Kinder M, Grugan KD, Soring KL, Carton J, Greenplate AR, Petley T, Capaldi D, Brosnan K, Emmell E, et al. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. Mabs 2014; 6:1265-73; PMID:25517311; http://dx.doi.org/10.4161/mabs.29825
   PubMed Web of Science ®Google Scholar
• Dijkers ECF, Kosterink JGW, Rademaker AP, Perk LR, van Dongen GAMS, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN. Development and characterization of clinical-grade Zr-89-Trastuzumab for HER2/neu immunopet imaging. J Nucl Med 2009; 50:974-81; PMID:19443585; http://dx.doi.org/10.2967/jnumed.108.060392
   PubMed Web of Science ®Google Scholar
• Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, Dreier B, Schibli R, Binz HK, Waibel R, et al. Efficient Tumor Targeting with High-Affinity Designed Ankyrin Repeat Proteins: Effects of Affinity and Molecular Size. Cancer Res 2010; 70:1595-605; PMID:20124480; http://dx.doi.org/10.1158/0008-5472.CAN-09-2724
   PubMed Web of Science ®Google Scholar
• van Dijk LK, Hoeben BAW, Kaanders JHAM, Franssen GM, Boerman OC, Bussink J. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and In-111-Labeled Cetuximab-F(ab ')(2). J Nucl Med 2013; 54:2118-24; PMID:24136932; http://dx.doi.org/10.2967/jnumed.113.123612
   PubMed Web of Science ®Google Scholar
• Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS. Noninvasive Imaging of PSMA in Prostate Tumors with Zr-89-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives. Mol Pharm 2014; 11:3965-73; PMID:24779727; http://dx.doi.org/10.1021/mp500164r
   PubMed Web of Science ®Google Scholar
• Marquez BV, Ikotun OF, Zheleznyak A, Wright B, Hari-Raj A, Pierce RA, Lapi SE. Evaluation of Zr-89-pertuzumab in Breast Cancer Xenografts. Mol Pharm 2014; 11:3988-95; PMID:25058168; http://dx.doi.org/10.1021/mp500323d
   PubMed Web of Science ®Google Scholar
• Scheuer W, van Dam GM, Dobosz M, Schwaiger M, Ntziachristos V. Drug-based optical agents: infiltrating clinics at lower risk (vol 4, 138er3, 2012). Sci Transl Med 2012; 4(134):134ps11,1-5; PMID:22593172; http://dx.doi.org/10.1126/scitranslmed.3003572
   PubMed Web of Science ®Google Scholar
• Dobosz M, Strobel S, Stubenrauch K-G, Osl F, Scheuer W. Noninvasive measurement of pharmacokinetics by near-infrared fluorescence imaging in the eye of mice. J Biomed Opt 2014; 19(1):1-8; PMID:24474508; http://dx.doi.org/10.1117/1.JBO.19.1.016022
   PubMed Web of Science ®Google Scholar
• Poeschinger T, Renner A, Weber T, Scheuer W. Bioluminescence imaging correlates with tumor serum marker, organ weights, histology, and human DNA levels during treatment of orthotopic tumor xenografts with antibodies. Mol Imaging Biol 2013; 15:28-39; PMID:22528864; http://dx.doi.org/10.1007/s11307-012-0559-x
   PubMed Web of Science ®Google Scholar
• Weber TG, Poeschinger T, Galban S, Rehemtulla A, Scheuer W. Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin. Neoplasia 2013; 15:863-74; PMID:23908588; http://dx.doi.org/10.1593/neo.13932
   PubMed Web of Science ®Google Scholar
• Weber TG, Osl F, Renner A, Poeschinger T, Galban S, Rehemtulla A, Scheuer W. Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively. Cancer Res 2014; 74:1913-23; PMID:24509903; http://dx.doi.org/10.1158/0008-5472.CAN-13-3001
   PubMed Web of Science ®Google Scholar
• Dobosz M, Ntziachristos V, Scheuer W, Strobel S. Multispectral fluorescence ultramicroscopy: three-dimensional visualization and automatic quantification of tumor morphology, drug penetration, and antiangiogenic treatment response. Neoplasia 2014; 16:1-U24; PMID:24563615; http://dx.doi.org/10.1593/neo.131848
   PubMed Web of Science ®Google Scholar